Literature DB >> 7191490

The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.

W C Koller, W J Weiner, B I Diamond, P A Nausieda, H L Klawans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7191490     DOI： 10.1016/0028-3908(80)90079-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


× No keyword cloud information.
  9 in total

1.  The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter.

Authors:  M R al-Sereiti; R F Quik; P Turner
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

2.  Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

3.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 4.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.

Authors:  J Arnt; J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 6.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

7.  Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum.

Authors:  K Fuxe; W T O'Connor; T Antonelli; P G Osborne; S Tanganelli; L F Agnati; U Ungerstedt
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

8.  The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.

Authors:  K Voith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Antagonism by domperidone of the ocular hypotensive effect of pergolide.

Authors:  M R al-Sereiti; R F Quik; A Hedges; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.